Find Pazopanib Hydrochloride manufacturers, exporters & distributors on PharmaCompass

Pazopanib

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

37 API Suppliers, 13 USDMF, 6 EU WC, 5 KDMF, 9 NDC API, 33 Listed Suppliers

DEVELOPMENTS

1 Drug(s) in Development

1 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Imports

INTERMEDIATES

35 Suppliers

35 Suppliers

DOSSIERs // Finished Dosage Formulations

23 Dossiers, 5 FDA Orange Book, 2 Europe, 1 Canada, 15 Listed Dossiers

DRUG PRODUCT COMPOSITION

TABLET;ORAL - EQ 200MG BASE, TABLET;ORAL - EQ 400MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 200MG BASE
TABLET;ORAL - EQ 400MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

Suppliers, 15 Kerry, 12 Seppic, 11 Roquette, 10 Corel Pharma Chem, 10 BASF, 9 Gangwal Chemicals, 9 Sigachi Industries, 9 Microlex e.U, 6 Gangwal Healthcare, 6 Lonza Capsugel, 5 Ideal Cures Pvt Ltd, 5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 3 Kima Chemical, 3 Prachin Chemical, 3 Vasa Pharmachem, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 3 Pharmatrans-Sanaq, 3 DFE Pharma, 2 Nanjing Well Pharmaceutical, 2 The Dow Chemical Company, 2 Actylis, 1 Clariant, 1 Nanjing Bold Chemical, 1 Ingredion Pharma Solutions, 1 Jai Radhe Sales, 1 SPI Pharma, 1 ACG Worldwide, 1 Qualicaps, 1 Ulanqab Kema New Material, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Boai NKY Pharmaceuticals Ltd

EXCIPIENTS BY APPLICATIONS

43 Coating Systems & Additives, 28 Fillers, Diluents & Binders, 23 Controlled & Modified Release, 18 Disintegrants & Superdisintegrants, 18 Solubilizers, 17 Direct Compression, 14 Thickeners and Stabilizers, 13 Granulation, 11 Lubricants & Glidants, 10 Film Formers & Plasticizers, 8 Parenteral, 7 Co-Processed Excipients, 5 Empty Capsules, 5 Emulsifying Agents, 5 Topical, 4 Vegetarian Capsules, 4 API Stability Enhancers, 4 Taste Masking, 4 Rheology Modifiers, 3 Surfactant & Foaming Agents, 3 Chewable & Orodispersible Aids, 2 Coloring Agents

GLOBAL SALES INFORMATION

8 US Medicaid Prescriptions

8 US Medicaid Prescriptions

MARKET PLACE

2 APIs, 5 DOSSIERS // FDF

PATENTS

2 Health Canada Patents

2 Health Canada Patents

ANALYTICAL SOLUTION(s)

1 BioAnalytical Methods

1 BioAnalytical Methods

DIGITAL CONTENT

1 Data Compilations & Company Tracker #PharmaFlow, 12 News

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

2,823

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

1,066.00

Annual Reports

828.00

FDF Market Place

EXCIPIENTS

141

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Also known as: 635702-64-6, Pazopanib hcl, Votrient, Pazopanib (hydrochloride), Armala, Unii-33y9anm545

Molecular Formula

C₂₁H₂₄ClN₇O₂S

Molecular Weight

474.0 g/mol

InChI Key

MQHIQUBXFFAOMK-UHFFFAOYSA-N

FDA UNII

33Y9ANM545

Pazopanib Hydrochloride is the hydrochloride salt of a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.

1 2D Structure

Pazopanib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide;hydrochloride

2.1.2 InChI

InChI=1S/C21H23N7O2S.ClH/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16;/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25);1H

2.1.3 InChI Key

MQHIQUBXFFAOMK-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N.Cl

2.2 Other Identifiers

2.2.1 UNII

33Y9ANM545

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Gw 780604

2. Gw 786034b

3. Gw-780604

4. Gw-786034b

5. Gw780604

6. Gw786034b

7. Pazopanib

8. Votrient

2.3.2 Depositor-Supplied Synonyms

1. 635702-64-6

2. Pazopanib Hcl

3. Votrient

4. Pazopanib (hydrochloride)

5. Armala

6. Unii-33y9anm545

7. Pazopanib Monohydrochloride

8. Pazopanib Hcl (gw786034 Hcl)

9. Gw786034b

10. Gw-786034b

11. Pazopanib (as Hydrochloride)

12. Gw786034 (hydrochloride)

13. 5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide;hydrochloride

14. Chebi:71217

15. 33y9anm545

16. S1035

17. 5-((4-((2,3-dimethyl-2h-indazol-6-yl)(methyl)amino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide Hydrochloride

18. 5-((4-((2,3-dimethyl-2h-indazol-6-yl)methylamino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide Monohydrochloride

19. 5-({4-[(2,3-dimethyl-2h-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzene-1-sulfonamide Hydrochloride

20. 5-{4-[(2,3-dimethyl-2h-indazol-6-yl)-methyl-amino]-pyrimidin-2-ylamino}-2-methyl-benzenesulfonamide Hydrochloride

21. Benzenesulfonamide, 5-((4-((2,3-dimethyl-2h-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-, Monohydrochloride

22. Patorma

23. Gw786034 Hcl

24. Votrient Hcl

25. Votrient (tn)

26. 5-({4-[(2,3-dimethyl-2h-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide Hydrochloride

27. Pazopanib Hydrochloride [usan:jan]

28. Mls004774147

29. Schembl159487

30. Pazopanib Hydrochloride- Bio-x

31. Pazopanib Hydrochloride [usan]

32. Chembl1201733

33. Dtxsid70212956

34. Ex-a956

35. Pazopanib Hcl (gw786034 )

36. Bcp02203

37. Pazopanib Hydrochloride (jan/usan)

38. Pazopanib Hydrochloride [mi]

39. Mfcd12546138

40. Nsc737754

41. Pazopanib Hydrochloride [jan]

42. Akos015958593

43. Bcp9001052

44. Ccg-269485

45. Cs-0126

46. Gsk-786034

47. Ks-1458

48. Nsc-737754

49. Pazopanib Hydrochloride [mart.]

50. Pb31655

51. Sb10367

52. Pazopanib Hydrochloride [who-dd]

53. Ac-24726

54. Bp166746

55. Hy-12009

56. Smr003500790

57. Am20090655

58. Ft-0687642

59. P2243

60. Pazopanib Hydrochloride [orange Book]

61. Sw218082-2

62. Ec-000.2347

63. D05380

64. A834417

65. Q27888072

66. 5-({4-[(2,3-dimethyl-2h-indazol-6-yl)(methyl)amino]-2-pyrimidinyl}amino)-2-methylbenzenesulfonamide Hydrochloride

67. 5-(4-((2,3-dimethyl-2h-indazol-6-yl)(methyl)amino)pyrimidin-2-ylamino)-2-methylbenzenesulfonamide Hydrochloride

68. 5-(4-((2,3-dimethyl-2h-indazol-6-yl)(methyl)amino)pyrimidin-2-ylamino)-2-methylbenzenesulfonamide Hydrochloride;5-[[4-[(2,3-dimethylindazol-6-yl)-methyl-amino]pyrimidin-2-yl]amino]-2-methyl-benzenesulfonamide Hydrochloride

69. 5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide Hydrochloride

70. Benzenesulfonamide, 5-[[4-[(2,3-dimethyl-2h-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-, Hydrochloride (1:1)

2.4 Create Date

2006-10-26

3 Chemical and Physical Properties

Molecular Formula	C₂₁H₂₄ClN₇O₂S
Molecular Weight	474.0 g/mol
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	5
Exact Mass	473.1400719 g/mol
Monoisotopic Mass	473.1400719 g/mol
Topological Polar Surface Area	127 Å²
Heavy Atom Count	32
Formal Charge	0
Complexity	717
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	2

4 Drug and Medication Information

4.1 Drug Information

1 of 2
Drug Name	Votrient
PubMed Health	Pazopanib (By mouth)
Drug Classes	Antineoplastic Agent, Immunological Agent
Active Ingredient	Pazopanib hydrochloride
Dosage Form	Tablet
Route	Oral
Strength	eq 200mg base; eq 400mg base
Market Status	Prescription
Company	Glaxosmithkline

2 of 2
Drug Name	Votrient
PubMed Health	Pazopanib (By mouth)
Drug Classes	Antineoplastic Agent, Immunological Agent
Active Ingredient	Pazopanib hydrochloride
Dosage Form	Tablet
Route	Oral
Strength	eq 200mg base; eq 400mg base
Market Status	Prescription
Company	Glaxosmithkline

4.2 Drug Indication

* Renal-cell carcinoma (RCC):

Votrient is indicated in adults for the first-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease.

* Soft-tissue sarcoma (STS):

Votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)adjuvant therapy.

Efficacy and safety have only been established in certain STS histological tumour subtypes.

5 Pharmacology and Biochemistry

5.1 FDA Pharmacological Classification

5.1.1 Pharmacological Classes

Cytochrome P450 2D6 Inhibitors [MoA]; Cytochrome P450 3A4 Inhibitors [MoA]; Kinase Inhibitor [EPC]; Protein Kinase Inhibitors [MoA]; Cytochrome P450 2C8 Inhibitors [MoA]

5.2 ATC Code

L01XE11

Market Place

Home

Post Enquiry

Market Place